Clay stabilization compositions include one or a plurality of triamino compounds and/or derivatives thereof, fluids containing an effective amount of the clay stabilization compositions and methods for making and using same.

Clay stabilization compositions include one or a plurality of triamino compounds and/or derivatives thereof, fluids containing an effective amount of the clay stabilization compositions and methods for making and using same.

Methods for syntheses of organic acids from α-keto acids, including methods for syntheses of isotopically enriched organic acids from α-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

Methods for syntheses of organic acids from α-keto acids, including methods for syntheses of isotopically enriched organic acids from α-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

Methods for syntheses of organic acids from α-keto acids, including methods for syntheses of isotopically enriched organic acids from α-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

Various salt forms of Compound I and Compound II represented by the following structural formulae, and their corresponding pharmaceutical compositions, are disclosed. (I), (II) Particular single crystalline forms of 1:1 Compound I tris salt, 1:1 Compound II tris salt, and 1:1 Compound II citrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

##STR00001##

Various salt forms of Compound I and Compound II represented by the following structural formulae, and their corresponding pharmaceutical compositions, are disclosed. (I), (II) Particular single crystalline forms of 1:1 Compound I tris salt, 1:1 Compound II tris salt, and 1:1 Compound II citrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

##STR00001##

The present invention relates to a plasticizer composition, a resin composition and a method for preparing thereof. The present invention can provide a plasticizer composition, which can improve properties required to the plasticizer composition contained in a vinyl chloride-based resin composition, such as plasticizing efficiency, volatile loss, and migration resistance, to a level equal to or better than the existing plasticizer composition, and a resin composition comprising thereof.

The present invention relates to a plasticizer composition, a resin composition and a method for preparing thereof. The present invention can provide a plasticizer composition, which can improve properties required to the plasticizer composition contained in a vinyl chloride-based resin composition, such as plasticizing efficiency, volatile loss, and migration resistance, to a level equal to or better than the existing plasticizer composition, and a resin composition comprising thereof.

A nickel hydroxide includes stacked nickel hydroxide layers. Each of the nickel hydroxide layers includes Ni.sup.2+ and OH.sup.−. At least one of the nickel hydroxide layers further includes a type of polyatomic anions. The polyatomic anions include a type of anions that are not SO.sub.4.sup.2− or CO.sub.3.sup.2−.